chevron_leftBack
As of 24 April 2025, Haisco Pharmaceutical Group Co., Ltd. has a market cap of $6.53B USD, ranking #2352 globally and #333 in China. It ranks #203 in the Healthcare sector, and #35 in the Biotechnology industry.
Key Stats
Market Cap
$6.53BUSD
47.61B CNY
Enterprise Value
$6.63BUSD
48.3B CNY
Revenue (TTM)
$510.68MUSD
3.72B CNY
EBITDA (TTM)
$68.39MUSD
498.35M CNY
Net Income (TTM)
$54.27MUSD
395.46M CNY
EBITDA Margin
13%
Profit Margin
11%
PE Ratio
122.6
Company Profile
Country (HQ)
Sector
Healthcare
Industry
Biotechnology
CEO
Xiu Lian Fan
open_in_new
Employees
5,337
Founded
2005
Website
haisco.com
open_in_new
warningChart data may be delayed
| 1d | 1w | 1m | 3m | 6m | 1y |
|---|---|---|---|---|---|
| -6.1% | -4.2% | 17% | 32% | 17% | 62% |
Markets
| Exchange | Ticker | Price |
|---|---|---|
|
002653
海思科医药集团股份有限公司 Class A
ISIN: CNE100001BC7
Shares Out.:
Shares Outstanding:
1.12B1
Shares Float:
493.868M2
TV:
TradingView:
SA:
Stock Analysis:
YF:
Yahoo Finance:
GF:
Google Finance:
BA:
Barron's:
MS:
Morningstar:
|
42.92 CNY |
1Market cap is calculated using shares outstanding.
2Float shares are publicly tradable shares, excluding insider-held stock.
About Haisco Pharmaceutical Group Co., Ltd.
Haisco Pharmaceutical Group Co., Ltd. research, develops, manufactures, and sells pharmaceuticals in China. The company offers cycloporol, dolasetron mesylate, polyene phosphatidylcholine, compound amino acid, and methylprednisolone sodium injections, as well as flupenthixol melitracen tablets. It offers its products in various therapeutic fields, including anesthesia, parenteral nutrition, tumor antiemetic, liver, gallbladder digestion, antibiotics, cardiovascular, and cerebrovascular. The company was formerly known as Xizang Haisco Pharmaceutical Group Co., Ltd. and changed its name to Haisco Pharmaceutical Group Co., Ltd. in March 2016. Haisco Pharmaceutical Group Co., Ltd. was founded in 2005 and is based in Shannan, China.
